Datum Källa Rubrik Typ Alternativ
2023-07-24 Ziccum Ziccum säkrar andra Feasibility-avtalet på två månader: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Ziccum Ziccums Q2-rapport - VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Ziccum ZICCUM AB (publ) Interim report Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-17 Ziccum Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation Pressreleaser Ladda ner | Visa Stäng
2023-06-19 Ziccum Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28 Pressreleaser Ladda ner | Visa Stäng
2023-06-05 Ziccum Ziccum joint proposal not selected for detailed application in current CEPI Call Pressreleaser Ladda ner | Visa Stäng
2023-06-02 Ziccum Ziccum appoints senior biopharma executive as new CFO Pressreleaser Ladda ner | Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit med Ziccum Pressreleaser Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit with Ziccum Pressreleaser Visa Stäng
2023-05-26 Ziccum Aerosol and inhalation authority Per Gerde joins Board of Directors of Ziccum AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Ziccum Ziccum CEO to present at BioStock Life Science Spring Summit Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Kommuniké från årsstämma i Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Bulletin from the Annual General Meeting of Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Ziccum Strategin ger resultat med betald studie i samarbete med toppbolag: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccums Q1-resultat: VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Ziccum KOMPLETTERING TILL KALLELSEN TILL ÅRSSTÄMMA I ZICCUM AB (PUBL), ATT HÅLLAS DEN 24 MAJ 2023, KL. 11.00 I BOLAGETS LOKALER PÅ SCHEELEVÄGEN 22 I LUND Pressreleaser Ladda ner | Visa Stäng
2023-05-02 Ziccum Ziccum AB filing three patent applications as part of new, expanded strategy to strengthen patent protection Pressreleaser Ladda ner | Visa Stäng
2023-04-26 Ziccum ZICCUM AB (publ) releases Interim report Q1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-24 Ziccum KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-03-20 Ziccum Ziccum reports positive results from drying of active mRNA and promising mRNA activity after powder reconstitution Pressreleaser Ladda ner | Visa Stäng
2023-03-17 Ziccum Ziccum to attend BIO-Europe Spring in Basel Pressreleaser Ladda ner | Visa Stäng
2023-03-10 Ziccum Ziccum AB joins innovative financial platform for Investor Relations management and European outreach Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Ziccum ZICCUM AB (publ) releases Annual Report 2022 Rapporter Ladda ner | Visa Stäng
2023-01-27 Ziccum ZICCUM AB (publ) Year-end report Q4 2022 Analyser Ladda ner | Visa Stäng
2023-01-23 Ziccum Ziccum submits Expression of Interest for CEPI funding Analyser Ladda ner | Visa Stäng
2023-01-18 Ziccum Ziccum CEO to present at international mRNA Summit in Berlin Analyser Ladda ner | Visa Stäng
2022-12-16 Ziccum Ziccum awarded 10 MSEK Eurostars funding for 3D-modeling and Digital twin project Analyser Ladda ner | Visa Stäng
2022-12-14 Ziccum Ziccum launches new, expanded website Analyser Ladda ner | Visa Stäng
2022-12-08 Ziccum Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project Analyser Ladda ner | Visa Stäng
2022-10-28 Ziccum Ziccums Q3-resultat: VD-uppdatering på svenska Analyser Ladda ner | Visa Stäng
2022-10-27 Ziccum ZICCUM AB (publ) Interim report Q3 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Ziccum Ziccum generates proof of successful drying of lipid nanoparticles in mRNA project Analyser Ladda ner | Visa Stäng
2022-09-27 Ziccum Ziccum reopens application for CEPI funding on thermostable vaccines with new partner Analyser Ladda ner | Visa Stäng
2022-09-23 Ziccum Ziccum receives results from evaluation study with leading Pharmaceutical Corporation Analyser Ladda ner | Visa Stäng
Analyser | 23 Sep 2022 | Ziccum

Ziccum receives results from evaluation study with leading Pharmaceutical Corporation

Ziccum AB (publ) (‘Ziccum’) has today received readout results from the latest stage of an evaluation agreement study carried out with a leading pharmaceutical corporation (previously communicated on June 3, 2022) analyzing LaminarPace’s ability to dry four test substances. Data demonstrated excellent results on thermostability, positive results on particle appearance but significant loss of infectivity, requiring further development. The client has paused assessment of LaminarPaceTM on the current vaccine platform, but will consider the technology in regard to other vaccine platforms, where dry formulation could be a higher priority.

The study analyzed LaminarPace’s ability to dry four test formulations from one of the client’s vaccine platform technologies from liquid into dry powders that would remain active and thermostable. Data were gathered from three key metrics: its virus count (an important metric of thermostability), the powder’s infectivity (its capability for vaccination efficiency), and its particle distribution. Also, the samples were exposed to so-called ‘temperature excursions’, with extended storage at both 40 and 55 degree C.

The readouts reveal that the LaminarPaceTM drying provides a very clear positive effect on thermostability, where the LaminarPaceTM technology preserves the viral particle count on excellent levels after prolonged heated storage, even in the extreme 55 degree C temperature testing. However, for the infectivity measures, this stage of testing resulted in significant loss of infectivity units, which will need further development work.

Regarding particle appearance, the LaminarPaceTM drying has given impressive particle preservation in microscopy analysis of the samples exposed to heated storage, compared to how these elevated temperatures normally are detrimental to the vaccine particles.

The study shows good potential for the LaminarPaceTM technology in vaccine drying.

Considering the need for continued development, the partner company is planning to stay with liquid formulations for the platform at hand at the present time, but will assess further information on the LaminarPaceTM technology since there are other vaccine platforms where dry formulation could be a higher priority.

Ziccum CEO Ann Gidner: “We are delighted to see this clear confirmation of thermostability, where LaminarPace is a game-changer. The activity preservation needs to be improved in further development for this vaccine platform, and we are happy to have recently implemented improved methodology for better experimental plan design, to address this and take the development forward.”

“Both parties in this collaboration learnt significantly from this process, and we achieved encouraging results. Our team at Ziccum has grown in capabilities and confidence over the course of this project, and we are delighted to have a good dialogue with our partner.”

2022-09-14 Ziccum Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding Analyser Ladda ner | Visa Stäng
2022-09-01 Ziccum Ziccum on the move: company to attend major industry events across Europe in 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Ziccum ZICCUM AB (publ) Interim report Q2 2022 Analyser Ladda ner | Visa Stäng

Kommande händelser

29 Apr 2024 | Kvartalsrapport 2024-Q1
17 May 2024 | Årligutdelning
30 Jul 2024 | Kvartalsrapport 2024-Q2
29 Oct 2024 | Kvartalsrapport 2024-Q3
29 Jan 2025 | Bokslutskommuniké 2024